title: Effects of estradiol-drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women.
abstract: OBJECTIVE
  To investigate the effects of a hormone replacement preparation containing 1 mg estradiol plus 2 mg drospirenone on menopausal symptoms, blood lipids, and bone turnover markers in postmenopausal women.
  
  
  METHODS
  A prospective, self-controlled trial was conducted in 64 Chinese postmenopausal women aged 45-60 (mean 52.5 ± 3.37) years who were treated with estradiol-drospirenone for at least 6 months. The Kupperman index, blood lipid concentrations, bone mineral density, and bone turnover markers were measured before (baseline) and at 1, 3, and 6 months after treatment.
  
  
  RESULTS
  In comparison with baseline, the Kupperman index score was significantly improved at 1, 3, and 6 months after estradiol-drospirenone treatment (20.57 ± 6.52 vs. 16.37 ± 5.19, 13.34 ± 4.52, and 12.70 ± 4.42, respectively; all p < 0.01). After 6 months of treatment, concentrations of low density lipoprotein cholesterol, triglycerides, and total cholesterol were significantly decreased, high density lipoprotein cholesterol concentrations were significantly increased (all p < 0.05), and bone mineral densities of the lumbar spine and hip were significantly improved (both p < 0.001 compared with baseline). At both 3 and 6 months after treatment, bone alkaline phosphatase concentrations were significantly decreased compared with baseline (61.14 ± 12.38 IU/l and 58.77 ± 11.35 IU/l, respectively, vs. 65.81 ± 14.75 IU/l; p < 0.05), as were tartrate-resistant acid phosphatase concentrations (5.99 ± 2.98 IU/l and 4.90 ± 2.90 IU/l, respectively, vs. 6.15 ± 3.02 IU/l; p < 0.05).
  
  
  CONCLUSIONS
  Estradiol-drospirenone effectively alleviates menopausal symptoms and also has beneficial effects on blood lipids and bone metabolism.
authors.affiliation: * Obstetrics and Gynecology Department of Navy General Hospital of Chinese PLA , Beijing.
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: A
authors.initials: A
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Hu
authors.forename: Z
authors.initials: Z
authors.lastname: Song
authors.forename: Y
authors.initials: Y
authors.lastname: Zhao
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: L
authors.initials: L
authors.lastname: Yan
authors.forename: X
authors.initials: X
authors.lastname: Li
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000736:Androstenes / Q000008:administration & dosage*; D015519:Bone Density; D016723:Bone Remodeling / Q000187:drug effects*; D002681:China; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000502:physiology*; D011446:Prospective Studies; D000071681:Tartrate-Resistant Acid Phosphatase; D014280:Triglycerides / Q000097:blood
chemical_list: D000736:Androstenes; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007527:Isoenzymes; D008055:Lipids; D014280:Triglycerides; D004958:Estradiol; D002784:Cholesterol; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; C035144:drospirenone
keywords: BLOOD LIPIDS; BONE METABOLISM; BONE TURNOVER MARKERS; ESTRADIOL–DROSPIRENONE; HORMONE REPLACEMENT THERAPY; MENOPAUSE